タスマン精神医学（第５版・全６巻）
Tasman’s Psychiatry 5th Edition

Editors: Allan Tasman, Michelle B. Riba, Renato D. Alarcón, César A. Alfonso, Shigenobu Kanba, Dusica Lecic-Tosevski, David M. Ndetei, Chee H. Ng, Thomas G. Schulze
2024:09 6 vols. 5,519 p. 320 illus., 257 in color.   ISBN 978-3-030-51365-8  (Springer) -DE-
EUR 429.99  Web販売価格：税込￥74,627 / 標準価格：税込￥96,488
機関向け電子版（Ebook Central）：Document ID: 31648822 / 標準価格：税込￥105,589

*2024年9月25日時点の価格です。実際の価格は、為替レートや出版社の都合により変動いたしますので、最新の価格は以下オンラインストアリンクをご参照ください。
*Web販売価格は、紀伊國屋書店BookWeb Proでご注文され、付帯作業を伴わない納品を行い、弊社標準書式による請求書を発行し遅滞なくお支払いただく場合、あるいは、クレジットカードでお支払いいただく場合に適用される販売価格です。
*Ebook Centralの詳細につきましては、こちらをご参照ください。

概要

初版刊行から30年、精神医学の重要テキストとして読み継がれてきた「タスマン精神医学」が全２巻から全６巻へと大幅に増補改訂し、およそ40の新章を追加して、10年ぶりに刊行されます。

本書は、500名を超える国際的に評価の高い編者と著者によって執筆されました。また、編集委員には日本の精神医学研究の第一人者である神庭重信氏（九州大学名誉教授・一般社団法人日本うつ病センター理事長）も名を連ねています。
前版に引き続き、本書は生物・心理・社会・文化的に統合された視点に基づいて、あらゆる経験水準の読者にとって必須かつ明解なレファレンスとして制作されました。この編集方針は、患者と臨床家のあいだの最初の出会い、その後の治療的関係を結び、患者と協力して治療計画を構築し、実行する過程の重要性を踏まえています。

加えて、精神保健の文化的・社会的決定要因への関心の高まりを受け、精神疾患の評価のセクションでは、ICD11とDSM 5-TRの両方の基準にもとづき論じています。また多くの章で、少なくとも２つの国または大陸の専門家が執筆しています。

精神医学分野を包括的にカバーするレファレンスとして生まれ変わった本書を、精神医学、心理学、臨床研究、ソーシャルワーク、カウンセリング、セラピーに携わる方々へおすすめいたします。

*前版情報：Psychiatry, 4th edition, 2 vols. (2014) ISBN 978-1-118-84547-9

価格照会・ご購入

• 紀伊國屋書店でご購入（一般の方向け）：紀伊國屋書店ウェブストア
• 紀伊國屋書店でご購入（法人の方向け）：紀伊國屋書店BookWeb Pro

※本件についてのお問い合わせ、お見積りについては最寄りの紀伊國屋書店営業所もしくはこちらまでお願いいたします。

収録明細

Volume 1

Section I Approaches to the Patient

1. Listening to the Patient
2. Cultural and Social Context of Clinical Assessment
3. The Physician–Patient Relationship
4. The Psychiatric Interview: General Structures and Techniques
5. The Psychiatric Interview: Adapting to Diverse Settings
6. Professional Ethics and Boundaries
7. Legal Issues in Psychiatric Practice

Section II Human Development Through the Life Cycle

8. Psychiatric Perspectives on Human Development
9. Infant Development: The First 3 Years of Life
10. Preschool Development
11. School-Age Development
12. Adolescent Development
13. Adult and Midlife Development
14. Late Life Development
15. Development of Personality Throughout the Life Cycle

Section III Neuroscientific Foundations of Psychiatry

16. Neurobiological Foundations of Psychiatry: Overview（Tadafumi Kato 加藤忠史 順天堂大学）
17. Evolutionary Psychiatry
18. Genetics of Psychiatric Disorders: Advances in Genetic Epidemiology and Genomic Approaches
19. Multiomics Approaches in Psychiatric Disorders
20. Gut Microbiome and Psychiatric Disorders
21. Gene-Environment Interactions
22. Cognitive Neuroscience
23. Neurobiology of Schizophrenia
24. Neurobiology of Mood Disorders
25. Neurobiology of Anxiety Disorders
26. Neurobiology of Addiction
27. Neurobiology of Autism Spectrum Disorder
28. Neurobiology of Attention Deficit Hyperactivity Disorder
29. Neurobiology of Dementia and Other Neurodegenerative Disorders
30. Neurobiology of Neuroimmune Encephalitic Disorders
31. Neurobiological Foundations of Psychotherapies

Volume 2

Section IV The Psychological and Social Scientific Foundations of Psychiatry

32. Psychiatric Epidemiology
33. Sociocultural Anthropology Models of Mental Function and Behavior
34. Social Psychology Models of Mental Function and Behavior
35. Psychoanalytic/Psychodynamic Models of Mental Function and Behavior
36. Cognitive and Behavioral Models of Mental Function and Behavior
37. Positive Psychology Model of Mental Function and Behavior

Section V Evaluation and Assessment in Psychiatry

38. Multimodal Clinical Evaluation and Treatment Planning
39. Consciousness, Memory, and Intelligence
40. Alterations of Speech, Thought, Perception, and Self-Experience
41. Emotions
42. Behavior and Adaptive Functioning
43. Physical Signs and Symptoms
44. Neuropsychological and Neurophysiological Assessment
45. Brain Imaging in Psychiatry
46. Integrative Neurobiological Approaches to Assessment
47. Assessment Tools in Psychiatry
48. Special Considerations in the Psychiatric Evaluation Across the Lifespan: Children, Adolescents, and the Elderly
49. Culture-Related Issues in Assessment
50. Special Issues in Assessment
51. ThePsychiatric Formulation

Section VI Disorders

52. Psychiatric Classification
53. Neurodevelopmental Disorders: Intellectual Disability
54. Neurodevelopmental Disorders: Speech and Language Disorders
55. Neurodevelopmental Disorders: Autism Spectrum Disorder
56. Neurodevelopmental Disorders: Attention Deficit Hyperactivity Disorder (ADHD)
57. Neurodevelopmental Disorders: Learning Disorders
58. Neurodevelopmental Disorders: Stereotypical Movement Disorders and Tic Disorders
59. Schizophrenia and Other Primary Psychotic Disorders
60. Bipolar Disorders
61. Depressive Disorders
62. Premenstrual Dysphoric Disorder, Peripartum (Perinatal) Depression, and Perimenopausal Depression
63. Childhood Mood Disorders: Depressive Disorders, Bipolar Disorders, and Disruptive Mood Dysregulation Disorder

Volume 3

64. Anxiety and Fear-Related Disorders: Generalized Anxiety Disorder
65. Anxiety and Fear-Related Disorders: Social Anxiety Disorder and Specific Phobia
66. Anxiety and Fear-Related Disorders: Panic Disorder and Agoraphobia
67. Anxiety Disorders in Youth: Separation Anxiety, Social Anxiety, and Generalized Anxiety Disorder
68. Obsessive-Compulsive Disorder
69. Obsessive-Compulsive Disorder Related Disorders: Hypochondriasis, Hoarding Disorder, Olfactory Reference Disorder, Body Dysmorphic Disorder, Trichotillomania, Excoriation Disorder
70. Disorders Specifically Associated with Stress: PTSD, Complex PTSD, Prolonged Grief Disorder, Acute Stress Reaction, Adjustment Disorder
71. Disorders Specifically Associated with Stress: Reactive Attachment Disorder and Disinhibited Social Engagement Disorder
72. Dissociative Disorders
73. Feeding and Eating Disorders
74. Childhood Elimination Disorders
75. Sleep and Sleep–Wake Disorders
76. Sexual Dysfunctions
77. Gender Incongruence
78. Disorders due to Substance Use: General Approaches
79. Disorders due to Substance Use: Alcohol Abuse and Addiction
80. Disorders due to Substance Use: Caffeine
81. Disorders due to Substance Use: Cannabis
82. Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances
83. Disorders due to Substance Use: Inhalants
84. Disorders Due to Substance Use: Nicotine
85. Disorders due to Substance Use: Opioids and Opioid Addiction
86. Disorders due to Substance Use: Phencyclidine
87. Disorders due to Substance Use: Sedatives, Hypnotics, and Anxiolytics
88. Disorders due to Substance Use: Stimulants

Volume 4

89. Gambling Disorder
90. Internet Gaming Disorder
91. Impulse Control Disorders: Intermittent Explosive Disorder, Kleptomania and Pyromania
92. Impulse Control Disorders: Oppositional Defiant Disorder and Conduct Disorder
93. Somatic Symptom and Related Disorders: Factitious Disorders
94. Disorders of Bodily Distress and Bodily Experience
95. Neurocognitive Disorders
96. Personality Disorders
97. Paraphilic Disorders
98. Relational Disorders
99. Culture and Psychopathology

Section VII Prevention, Systems of Care, and Psychosocial Aspects of Treatment

100. Prevention in Psychiatry
101. Systems of Care
102. Mental Health Care Models in Low- and Middle-Income Countries
103. The Recovery Model and Other Rehabilitative Approaches
104. Psychosocial Interventions to Support Community Living: Rehabilitation, Recovery, and Rights
105. Early Intervention Across Mental Health Services
106. Addressing the Social Determinants of Mental Health to Achieve Equitable Clinical Care, Research, Education, and Public Policy

Section VIII Psychotherapeutic Treatments

107. Supportive Psychotherapy
108. Individual Psychodynamic Psychotherapy
109. Brief Psychotherapies
110. Cognitive and Behavioral Therapies
111. Dialectical Behavioral Therapy
112. Mindfulness-Based Cognitive Therapy
113. Interpersonal Psychotherapy
114. Motivational Interviewing
115. Hypnosis
116. Group Psychotherapy
117. Family and Couple Therapy
118. Mindfulness-Based Interventions for Psychiatry
119. Combined Psychotherapy and Somatic Treatments

Volume 5

Section IX Pharmacological and Other Somatic Treatments

120. General Principles of Pharmacologic Therapy（Ken Inada　稲田健　北里大学、Shigeto Yamawaki　山脇　成人　広島大学、Shigenobu Kanba 神庭重信　九州大学、Gen Shinozaki　篠崎元　スタンフォード大学 and Siegfried Kasper）
121. Neuroscience-Based Nomenclature (NbN): A New Pharmacological Driven Classification of Psychotropics
122. Pharmacogenomics and Precision Psychiatry
123. Cultural and Ethnic Perspectives in Psychopharmacology (Keh-Ming Lin, Mario Braakman, Kazutaka Shimoda　下田和孝　独協医科大学　and Norio Yasui-Furukori　古郡規雄　独協医科大学）
124. Adherence with Medication Treatment in Psychiatric Disorders （Yumi Aoki　青木裕見　聖路加国際大学、Hiroyoshi Takeuchi　竹内啓善　慶應大学、Koichiro Watanabe　渡邊衡一郎　杏林大学, and Allan Tasman）
125. Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
126. Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics) （Hiroyuki Uchida　内田裕之　慶應大学、Euitae Kim, L. Fredrik Jarskog, W. Wolfgang Fleischhacker, Gary Remington, and Jeffrey A. Lieberman）
127. Medications for Bipolar Disorder
128. Medications for Anxiety Disorders （Zui Narita, Michiko Fujimoto　藤本美智子　大阪大学、 Elizabeth Winter, Paul Nestadt, and Akira Sawa　澤 明　ジョンズホプキンス大学）
129. Pharmacologic Treatment of Insomnia （Kazuo Mishima　三島和夫　秋田大学）
130. Therapeutic Use of Dopamine Enhancers (Stimulants)
131. Cognitive Enhancers and Treatments for Alzheimer’s Disease
132. Pharmacological Treatment of Substance Use Disorders
133. Medical Use of Cannabinoids and Psychedelic Compounds
134. Treatments for Medication-Induced Movement Disorders
135. Pharmacologic Management of Reproductive Psychopathology
136. Somatic Treatments and Neuromodulation in Psychiatry
137. Integrative and Complementary Medicine in Psychiatry
138. Placebo and Nocebo Effects: Biological and Cultural Aspects

Section X Consultation Liaison and Collaborative Care in Medical Illness and Comorbid Psychiatric and Medical Illnesses

139. Integrated and Collaborative Models of Care
140. Pediatric Consultation and Liaison Psychiatry
141. Psychiatric Conditions During Peripartum and Perimenopause
142. Consultation-Liaison Psychiatry and Psychological Factors Affecting Other Medical Conditions
143. Collaborative Care and Geriatric Psychiatry
144. Determination of Decisional Capacity
145. Palliative Care and Pain Management
146. Death and Bereavement

Volume 6

Section XI Treatment Issues in Specific Populations and Settings

147. LGBTQ Individuals
148. Forensic Psychiatry
149. Psychiatry in Prisons and Corrections
150. Intimate Partner and Sexual Violence
151. Managing Psychological Consequences in Disaster Populations
152. Migration Mental Health: Immigrants, Refugees, and Displaced Persons
153. Victims of Torture
154. Managing Workplace Mental Health: Multiple Approaches at Patient, Provider, and Systems Levels

Section XII Emergency Psychiatry

155. Modern Psychiatric Emergency Care
156. Assessment and Management of Suicidal Risk
157. Assessment and Management of Violent Behavior
158. Assessment and Management of Agitation
159. Restraint and Seclusion

Section XIII Digital Mental Health Services and Technologies

160. Telepsychiatry
161. Integrated Digital Platforms for Clinical Care
162. Online Consumer Tools and Support
163. Online Psychological Therapy
164. Devices, Mobile Health, and Digital Phenotyping
165. Predictive Modeling, Artificial Intelligence, and Machine Learning in Psychiatric Assessment and Treatment

Section XIV Appendices

166. Brief History of Psychiatry
167. Research Methodology and Statistics
168. Climate Change and Psychiatry
169. Global Perspectives on Psychiatric Education

Index

（学術洋書部）